ACQUISITION, Part V (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended	12 Months Ended			24 Months Ended
	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Jun. 25, 2012
Unaudited pro forma financial information [Abstract]
Revenues		$ 331,370	$ 338,416
Net income (loss)		(35,500)	(24,529)
Diluted earnings per share (in dollars per share)		$ (0.50)	$ (0.35)
Business Acquisition, Cost of Acquired Entity, Acceleration of Stock Options		8,265			8,265	8,265
Income tax (benefit) provision related to acquisition after recast	37,093	37,093	0	0
Business Acquisition, Cost of Acquired Entity, Transaction Costs Duration		6,145	2,936		9,081
Business Acquisition, Cost of Acquired Entity, Transaction Costs incurred by eBioscience		$ 5,470	$ 644